These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 21317202)
1. The novel Raf inhibitor Raf265 decreases Bcl-2 levels and confers TRAIL-sensitivity to neuroendocrine tumour cells. Zitzmann K; de Toni E; von Rüden J; Brand S; Göke B; Laubender RP; Auernhammer CJ Endocr Relat Cancer; 2011 Apr; 18(2):277-85. PubMed ID: 21317202 [TBL] [Abstract][Full Text] [Related]
2. Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease. Zitzmann K; Rüden Jv; Brand S; Göke B; Lichtl J; Spöttl G; Auernhammer CJ Cancer Lett; 2010 Sep; 295(1):100-9. PubMed ID: 20356670 [TBL] [Abstract][Full Text] [Related]
3. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Höpfner M; Baradari V; Huether A; Schöfl C; Scherübl H Endocr Relat Cancer; 2006 Mar; 13(1):135-49. PubMed ID: 16601284 [TBL] [Abstract][Full Text] [Related]
4. The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Llobet D; Eritja N; Yeramian A; Pallares J; Sorolla A; Domingo M; Santacana M; Gonzalez-Tallada FJ; Matias-Guiu X; Dolcet X Eur J Cancer; 2010 Mar; 46(4):836-50. PubMed ID: 20071162 [TBL] [Abstract][Full Text] [Related]
5. Enhanced susceptibility to tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in oral squamous cell carcinoma cells treated with phosphatidylinositol 3-kinase inhibitors. Uchida M; Iwase M; Takaoka S; Yoshiba S; Kondo G; Watanabe H; Ohashi M; Nagumo M; Shintani S Int J Oncol; 2007 May; 30(5):1163-71. PubMed ID: 17390018 [TBL] [Abstract][Full Text] [Related]
6. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation. Hamaï A; Richon C; Meslin F; Faure F; Kauffmann A; Lecluse Y; Jalil A; Larue L; Avril MF; Chouaib S; Mehrpour M Oncogene; 2006 Dec; 25(58):7618-34. PubMed ID: 16983347 [TBL] [Abstract][Full Text] [Related]
7. The sesquiterpene lactone eupatolide sensitizes breast cancer cells to TRAIL through down-regulation of c-FLIP expression. Lee J; Hwangbo C; Lee JJ; Seo J; Lee JH Oncol Rep; 2010 Jan; 23(1):229-37. PubMed ID: 19956887 [TBL] [Abstract][Full Text] [Related]
8. Myricetin sensitizes malignant glioma cells to TRAIL-mediated apoptosis by down-regulation of the short isoform of FLIP and bcl-2. Siegelin MD; Gaiser T; Habel A; Siegelin Y Cancer Lett; 2009 Oct; 283(2):230-8. PubMed ID: 19398149 [TBL] [Abstract][Full Text] [Related]
9. Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Kang J; Bu J; Hao Y; Chen F Prostate Cancer Prostatic Dis; 2005; 8(3):274-9. PubMed ID: 15897917 [TBL] [Abstract][Full Text] [Related]
10. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT. Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274 [TBL] [Abstract][Full Text] [Related]
11. mTOR, p70S6K, AKT, and ERK1/2 levels predict sensitivity to mTOR and PI3K/mTOR inhibitors in human bronchial carcinoids. Gagliano T; Bellio M; Gentilin E; Molè D; Tagliati F; Schiavon M; Cavallesco NG; Andriolo LG; Ambrosio MR; Rea F; Degli Uberti E; Zatelli MC Endocr Relat Cancer; 2013 Aug; 20(4):463-75. PubMed ID: 23653462 [TBL] [Abstract][Full Text] [Related]
12. The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Miyashita K; Shiraki K; Fuke H; Inoue T; Yamanaka Y; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T Int J Mol Med; 2006 Aug; 18(2):249-56. PubMed ID: 16820931 [TBL] [Abstract][Full Text] [Related]
13. TRAIL apoptosis is enhanced by quercetin through Akt dephosphorylation. Kim YH; Lee YJ J Cell Biochem; 2007 Mar; 100(4):998-1009. PubMed ID: 17031854 [TBL] [Abstract][Full Text] [Related]
14. Sensitization of tumor cells to Apo2 ligand/TRAIL-induced apoptosis by inhibition of casein kinase II. Ravi R; Bedi A Cancer Res; 2002 Aug; 62(15):4180-5. PubMed ID: 12154014 [TBL] [Abstract][Full Text] [Related]
15. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells. Izeradjene K; Douglas L; Delaney A; Houghton JA Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455 [TBL] [Abstract][Full Text] [Related]
16. Metformin sensitizes human bladder cancer cells to TRAIL-induced apoptosis through mTOR/S6K1-mediated downregulation of c-FLIP. Zhang T; Wang X; He D; Jin X; Guo P Anticancer Drugs; 2014 Sep; 25(8):887-97. PubMed ID: 24714080 [TBL] [Abstract][Full Text] [Related]
17. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2- or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Walczak H; Bouchon A; Stahl H; Krammer PH Cancer Res; 2000 Jun; 60(11):3051-7. PubMed ID: 10850456 [TBL] [Abstract][Full Text] [Related]
18. The coffee diterpene kahweol sensitizes TRAIL-induced apoptosis in renal carcinoma Caki cells through down-regulation of Bcl-2 and c-FLIP. Um HJ; Oh JH; Kim YN; Choi YH; Kim SH; Park JW; Kwon TK Chem Biol Interact; 2010 Jun; 186(1):36-42. PubMed ID: 20403343 [TBL] [Abstract][Full Text] [Related]
19. Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: a potential mechanism of therapeutic limitation of mTOR inhibitor. Iida S; Miki Y; Ono K; Akahira J; Nakamura Y; Suzuki T; Sasano H Mol Cell Endocrinol; 2012 Mar; 350(1):99-106. PubMed ID: 22178087 [TBL] [Abstract][Full Text] [Related]
20. Berberine sensitizes TRAIL-induced apoptosis through proteasome-mediated downregulation of c-FLIP and Mcl-1 proteins. Lee SJ; Noh HJ; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ Int J Oncol; 2011 Feb; 38(2):485-92. PubMed ID: 21170508 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]